文献速递前列腺癌

瑞格列克与亮丙瑞林对晚期前列腺癌男性生活质量的影响:3期HERO研究结果

Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
PubMed 文献 · Eur Urol · 2023-10-11

HERO研究为3期随机对照研究,934例晚期前列腺癌患者按2:1随机接受口服瑞格列克120 mg每日一次或亮丙瑞林3个月注射共48周,治疗期间两组EORTC QLQ-C30与QLQ-PR25自基线变化无统计学显著差异;睾酮恢复期瑞格列克组激素治疗相关症状评分低于亮丙瑞林组,提示激素相关症状负担更低,但该亚组患者数少。

要点

  • 治疗至结束时,两组EORTC QLQ-C30和QLQ-PR25评分自基线变化无统计学显著差异。
  • 睾酮恢复期,瑞格列克组激素治疗相关症状评分低于亮丙瑞林组。
  • 口服瑞格列克患者报告的健康相关生活质量与亮丙瑞林相似。

核心结论

  • 口服瑞格列克是与亮丙瑞林患者报告健康相关生活质量相似的治疗选择,为雄激素剥夺治疗提供口服方案且与更快的睾酮下降相关。

研究设计与样本

  • 3期随机对照研究,纳入934例晚期前列腺癌患者,按2:1随机接受瑞格列克120 mg口服每日一次或亮丙瑞林3个月注射共48周。
  • 睾酮恢复在患者亚组中评估;HRQOL评估基于EORTC QLQ-C30和EORTC QLQ-PR25,并在事后分析中评估HRQOL恶化的预测因素。

主要发现

  • 治疗至结束时,两组EORTC QLQ-C30或EORTC QLQ-PR25自基线变化均无统计学显著差异。
  • 睾酮恢复期,瑞格列克组激素治疗相关症状评分低于亮丙瑞林组,提示与治疗后睾酮恢复更快的治疗相关的激素相关症状负担更低。

临床怎么用

  • 作者认为口服瑞格列克是与亮丙瑞林患者报告健康相关生活质量相似的治疗选择,为雄激素剥夺治疗提供口服方案且与更快的睾酮下降相关。

局限性

  • 睾酮恢复组患者数量少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, demonstrated testosterone suppression to castrate levels in men with advanced prostate cancer (PCa) in the HERO study. Since advanced PCa and its treatments can impact patients' daily life, it is imperative to understand the impact of systemic therapy on patient health-related quality of life (HRQOL). OBJECTIVE: To report the HRQOL for patients on relugolix compared with those on leuprolide in on-treatment and testosterone recovery periods of the HERO study. DESIGN, SETTING, AND PARTICIPANTS: A phase 3 randomized controlled study was conducted in 934 patients with advanced PCa. INTERVENTION: Patients underwent 2:1 randomization and received relugolix 120 mg orally once daily or leuprolide 3-mo injections for 48 wk. Testosterone recovery was evaluated in a patient subset. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: HRQOL evaluations were based on the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30) and the Prostate Cancer Module (EORTC QLQ-PR25) during treatment and testosterone recovery phases. In a post hoc analysis, predictors of HRQOL deterioration were evaluated. RESULTS AND LIMITATIONS: No statistically significant differences between the two groups were found in changes from baseline to the end of treatment in either the EORTC QLQ-C30 or the EORTC QLQ-PR25 instrument. During the testosterone recovery phase, hormonal treatment-related symptoms scores were lower for relugolix than for leuprolide, suggesting a lower burden of hormone-related symptoms associated with a treatment that has more rapid testosterone recovery after treatment cessation. Limitations include low patient numbers in the testosterone recovery group. CONCLUSIONS: Oral relugolix is a therapeutic option with similar patient-reported HRQOL to leuprolide, providing an oral option for androgen deprivation therapy associated with a more rapid testosterone reduction. PATIENT SUMMARY: In men with advanced prostate cancer, relugolix had similar health-related quality of life to leuprolide.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Tombal B, Collins S, Morgans AK, et al. Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. Eur Urol. 2023. PMID: 37833178. doi:10.1016/j.eururo.2023.09.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。